Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.61 |
| ▸ | MMP3 | P08254 | 11/20 | 0.61 |
| ▸ | MMP9 | P14780 | 11/20 | 0.61 |
| ▸ | MMP13 | P45452 | 10/20 | 0.61 |
| ▸ | MMP1 | P03956 | 7/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893160 | 0.99 | MMP2 (0.61) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7894228 | 0.99 | MMP2 (0.61) | MMP2MMP3MMP9MMP13MMP1 | |
| Potassium Ion SCHEMBL7893163 | 0.90 | MMP2 (0.60) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7894234 | 0.90 | MMP2 (0.60) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7893154 | 0.90 | MMP2 (0.55) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7554346 | 0.90 | MMP2 (0.57) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7886287 | 0.88 | MMP2 (0.53) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL6292126 | 0.87 | MMP2 (0.64) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7551832 | 0.86 | MMP2 (0.62) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL8203574 | 0.85 | MMP2 (0.51) | MMP2MMP3MMP9MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923530-B1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS | BAYER AG (US) | 2004-09-01 | — | — | EP | claimed |
| US-6762184-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-07-13 | — | — | US | claimed |
| US-6911449-B2 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| EP-0923530-B1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS | BAYER AG (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6762184-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6762184-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-6500847-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER CORPORATION | 2002-12-31 | — | — | US | disclosed |
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6225314-B1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER CORPORATION | 2001-05-01 | — | — | US | disclosed |
| EP-1087761-A2 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES | Bayer Aktiengesellschaft (DE) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000050017-A2 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-08-31 | — | — | WO | disclosed |
| EP-1031349-A1 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases | Bayer Aktiengesellschaft (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP26 | MMP2 13/4885MMP3 21/4885MMP9 15/4885 |
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP13 | MMP2 12/4885MMP3 23/4885MMP9 9/4885 |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | ADAMTS5, ADAMTS1, ADAMTS4 | MMP2 12/4885MMP3 29/4885MMP9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.